177 related articles for article (PubMed ID: 15078089)
21. Control of the pathogenic conformational change of the prion protein by an attractor of low order.
Havsteen BH
J Theor Biol; 2004 Nov; 231(1):39-48. PubMed ID: 15363928
[TBL] [Abstract][Full Text] [Related]
22. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils.
Bocharova OV; Breydo L; Salnikov VV; Baskakov IV
Biochemistry; 2005 May; 44(18):6776-87. PubMed ID: 15865423
[TBL] [Abstract][Full Text] [Related]
23. Methionine oxidation interferes with conversion of the prion protein into the fibrillar proteinase K-resistant conformation.
Breydo L; Bocharova OV; Makarava N; Salnikov VV; Anderson M; Baskakov IV
Biochemistry; 2005 Nov; 44(47):15534-43. PubMed ID: 16300402
[TBL] [Abstract][Full Text] [Related]
24. Scrapie-infected cells, isolated prions, and recombinant prion protein: a comparative study.
Kneipp J; Miller LM; Spassov S; Sokolowski F; Lasch P; Beekes M; Naumann D
Biopolymers; 2004 May-Jun 5; 74(1-2):163-7. PubMed ID: 15137116
[TBL] [Abstract][Full Text] [Related]
25. Conformational properties of peptide fragments homologous to the 106-114 and 106-126 residues of the human prion protein: a CD and NMR spectroscopic study.
Di Natale G; Impellizzeri G; Pappalardo G
Org Biomol Chem; 2005 Feb; 3(3):490-7. PubMed ID: 15678187
[TBL] [Abstract][Full Text] [Related]
26. Oxidation of methionine residues in the prion protein by hydrogen peroxide.
Requena JR; Dimitrova MN; Legname G; Teijeira S; Prusiner SB; Levine RL
Arch Biochem Biophys; 2004 Dec; 432(2):188-95. PubMed ID: 15542057
[TBL] [Abstract][Full Text] [Related]
27. Modeling a prion protein dimer: predictions for fibril formation.
Warwicker J
Biochem Biophys Res Commun; 2000 Nov; 278(3):646-52. PubMed ID: 11095963
[TBL] [Abstract][Full Text] [Related]
28. Effects of detergents on the secondary structures of prion protein peptides as studied by CD spectroscopy.
Kuroda Y; Maeda Y; Sawa S; Shibata K; Miyamoto K; Nakagawa T
J Pept Sci; 2003 Apr; 9(4):212-20. PubMed ID: 12725242
[TBL] [Abstract][Full Text] [Related]
29. In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features.
Baskakov IV; Bocharova OV
Biochemistry; 2005 Feb; 44(7):2339-48. PubMed ID: 15709746
[TBL] [Abstract][Full Text] [Related]
30. PrP N-terminal domain triggers PrP(Sc)-like aggregation of Dpl.
Erlich P; Cesbron JY; Lemaire-Vieille C; Curt A; Andrieu JP; Schoehn G; Jamin M; Gagnon J
Biochem Biophys Res Commun; 2008 Jan; 365(3):478-83. PubMed ID: 17997980
[TBL] [Abstract][Full Text] [Related]
31. Generation of genuine prion infectivity by serial PMCA.
Weber P; Giese A; Piening N; Mitteregger G; Thomzig A; Beekes M; Kretzschmar HA
Vet Microbiol; 2007 Aug; 123(4):346-57. PubMed ID: 17493773
[TBL] [Abstract][Full Text] [Related]
32. Structural dependence of the cellular isoform of prion protein on solvent: spectroscopic characterization of an intermediate conformation.
Pergami P; Bramanti E; Ascoli GA
Biochem Biophys Res Commun; 1999 Nov; 264(3):972-8. PubMed ID: 10544040
[TBL] [Abstract][Full Text] [Related]
33. Structure of the recombinant full-length hamster prion protein PrP(29-231): the N terminus is highly flexible.
Donne DG; Viles JH; Groth D; Mehlhorn I; James TL; Cohen FE; Prusiner SB; Wright PE; Dyson HJ
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13452-7. PubMed ID: 9391046
[TBL] [Abstract][Full Text] [Related]
34. Dynamics of a truncated prion protein, PrP(113-231), from (15)N NMR relaxation: order parameters calculated and slow conformational fluctuations localized to a distinct region.
O'Sullivan DB; Jones CE; Abdelraheim SR; Brazier MW; Toms H; Brown DR; Viles JH
Protein Sci; 2009 Feb; 18(2):410-23. PubMed ID: 19173221
[TBL] [Abstract][Full Text] [Related]
35. The elusive intermediate on the folding pathway of the prion protein.
Jenkins DC; Sylvester ID; Pinheiro TJ
FEBS J; 2008 Mar; 275(6):1323-35. PubMed ID: 18279390
[TBL] [Abstract][Full Text] [Related]
36. Conformational flexibility of a human immunoglobulin light chain variable domain by relaxation dispersion nuclear magnetic resonance spectroscopy: implications for protein misfolding and amyloid assembly.
Mukherjee S; Pondaven SP; Jaroniec CP
Biochemistry; 2011 Jul; 50(26):5845-57. PubMed ID: 21627161
[TBL] [Abstract][Full Text] [Related]
37. Observation of intermediate states of the human prion protein by high pressure NMR spectroscopy.
Kachel N; Kremer W; Zahn R; Kalbitzer HR
BMC Struct Biol; 2006 Jul; 6():16. PubMed ID: 16846506
[TBL] [Abstract][Full Text] [Related]
38. Solid-state NMR structural studies of the fibril form of a mutant mouse prion peptide PrP89-143(P101L).
Lim KH; Nguyen TN; Damo SM; Mazur T; Ball HL; Prusiner SB; Pines A; Wemmer DE
Solid State Nucl Magn Reson; 2006 Feb; 29(1-3):183-90. PubMed ID: 16256316
[TBL] [Abstract][Full Text] [Related]
39. Disulfide bond isomerization in basic pancreatic trypsin inhibitor: multisite chemical exchange quantified by CPMG relaxation dispersion and chemical shift modeling.
Grey MJ; Wang C; Palmer AG
J Am Chem Soc; 2003 Nov; 125(47):14324-35. PubMed ID: 14624581
[TBL] [Abstract][Full Text] [Related]
40. Characterization of micros-ms dynamics of proteins using a combined analysis of 15N NMR relaxation and chemical shift: conformational exchange in plastocyanin induced by histidine protonations.
Hass MA; Thuesen MH; Christensen HE; Led JJ
J Am Chem Soc; 2004 Jan; 126(3):753-65. PubMed ID: 14733549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
